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Abstract 21 
Carbapenem resistant Acinetobacter baumannii is becoming increasingly prevalent in 22 
patients with diabetes mellitus in the Middle East. We examined the relationship between 23 
these bacteria and their resistance mechanisms with the diabetic disease status of patients. 24 
Susceptibilities of 271 isolates to carbapenems, tigecycline and colistin were determined, 25 
followed by detection of carbapenemase genes. A blaVIM gene was detected in ~95% isolates; 26 
blaOXA-23 and blaOXA-40 genes were also prevalent. Diabetic patients were significantly more 27 
likely to carry carbapenem-resistant isolates. Carbapenem resistant A. baumannii is a serious 28 
problem in diabetics, and molecular detection of resistance mechanisms in these isolates is 29 
required. 30 
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Introduction 46 
One of the greatest threats to modern medicine is the increasing prevalence of antibiotic-47 
resistant bacteria, particularly Gram-negative bacteria (Boucher et al., 2009). One of these 48 
bacteria, Acinetobacter baumannii, has risen to prominence due to the international 49 
dissemination of multidrug-resistant lineages resistant to the carbapenem antibiotics (Higgins 50 
et al., 2009; Towner et al., 2008; Turton et al., 2007). A. baumannii can become resistant to 51 
the carbapenems through a number of mechanisms including expression of OXA-type 52 
carbapenemases and expression of an acquired metallo-β-lactamase (Evans et al., 2013; 53 
Turton et al., 2006). Recent studies have shown that the prevalence of carbapenem-resistant 54 
A. baumannii can be incredibly high in the Middle East (Al Johani et al., 2010; Mugnier et 55 
al., 2009). 56 
Another growing health concern particularly prominent in the Middle East is the increase in 57 
the number of people with diabetes mellitus (Danaei et al., 2011). Diabetes mellitus has been 58 
shown to be a significant risk factor in the acquisition of serious hospital-acquired infections 59 
with A. baumannii (Metan et al., 2009; Michalopoulos et al., 2011; Prata-Rocha et al., 2012). 60 
The combination of increasing prevalence of diabetic patients and of carbapenem-resistant A. 61 
baumannii, to which these patients appear to be particularly susceptible, presents a worrying 62 
scenario of a rapidly rising number of difficult-to-treat infections. In order to begin to 63 
understand the nature of this problem, we investigated the prevalence of carbapenem-resistant 64 
A. baumannii and the β-lactamase genes they carry in both diabetic and non-diabetic patients 65 
from hospitals across Saudi Arabia. 66 
 67 
Methods 68 
A total of 271 isolates preliminarily identified as A. baumannii obtained from patients from 69 
intensive care units (ICUs) in hospitals in Saudi Arabia between 2008 and 2011 were selected 70 
for inclusion in the study. Isolates were confirmed as A. baumannii using the Vitek compact 71 
II system and detection of a blaOXA-51-like gene by PCR (Woodford et al., 2006). These 271 72 
isolates comprised two distinct groups. One group of 196 isolates were selected for inclusion 73 
due to initial identification as being carbapenem resistant, and of these, 84 were obtained 74 
from patients with diabetes mellitus. Patients were defined as being diabetic if they were 75 
insulin users and being treated for diabetes under the care of a hospital. The remaining 75 of 76 
the 271 isolates were selected for inclusion at random without any prior knowledge about the 77 
antimicrobial sensitivity of the isolates or the diabetic status of the patients they were 78 
obtained from, with the exception that all isolates included in the study came from different 79 
patients. Of the group of 75 randomly selected isolates, 20 were obtained from diabetic 80 
patients. Detection of β-lactamase genes and insertion sequences was performed as described 81 
previously (Ellington et al., 2007; Poirel & Nordmann, 2006; Woodford et al., 2006). 82 
Antibiotic MICs were determined by the plate doubling dilution method according to British 83 
Society for Antimicrobial Chemotherapy (BSAC) guidelines (Andrews, 2010). As no 84 
breakpoint for tigecycline exists for A. baumannii, the breakpoint for Enterobacteriacea was 85 
used. For statistical analyses, isolates showing an intermediate level of antibiotic resistance 86 
were grouped with resistant isolates. Analyses were performed in SPSS v.20 (SPSS Inc, 87 
Chicago, IL, USA), and where appropriate were corrected for multiple testing (Benjamini & 88 
Hochberg, 1995).  89 
 90 
Results and Discussion 91 
The isolates included in the study came from a total of 37 hospitals and a wide range of 92 
samples including blood, respiratory, urine and wound. Of the 24 hospitals contributing more 93 
than one isolate, 9 contributed isolates from both diabetic and non-diabetic patients. Analyses 94 
were first performed on the data by dividing it into the isolates selected because they were 95 
carbapenem resistant, and those selected randomly (Table 1). Combining the datasets for 96 
analysis was not possible as the method of isolate selection would bias the results. 97 
Determination of antibiotic MICs confirmed that carbapenem resistance was found in almost 98 
all isolates selected for this trait, with only 6 of the 196 isolates (3%) having lost resistance to 99 
both imipenem and meropenem during storage. Carbapenem resistance was also prevalent in 100 
the randomly selected isolates, with a patient being more likely to carry a carbapenem-101 
resistant isolate than not (chi squared test, χ2 = 7.053, d.f. = 1, p = 0.008). A high proportion 102 
of isolates (99%) carried genes for at least one acquired carbapenem-hydrolysing β-103 
lactamase, with blaVIM sequences particularly prevalent. Of the 32 carbapenem-susceptible 104 
isolates, 29 (91%) were positive for a blaVIM gene.  105 
The data were then analysed with respect to the disease status of the patient. Overall there is a 106 
significantly higher proportion of diabetic patients in the carbapenem-resistant isolate group 107 
than in the randomly selected isolate group (44% and 28% respectively, chi squared test, χ2 = 108 
5.787, d.f. = 1, p = 0.016). The data were then sub-divided into those isolates that were 109 
obtained from patients with diabetes, and those obtained from non-diabetics. Analyses were 110 
performed on all categories for which there were enough data (Table 2). Amongst the 111 
randomly selected isolates, diabetic patients were significantly more likely to carry an isolate 112 
with a blaOXA-23 gene or for it to be carbapenem-resistant, consistent with the previous finding 113 
above that diabetics are over-represented in the carbapenem-resistant isolate group. In the 114 
carbapenem-resistant isolate group, diabetic patients were significantly more likely to carry 115 
an isolate with an ISAba2 or ISAba3 insertion sequence, and significantly less likely to carry 116 
a tigecycline-resistant isolate. A similar result was found in the randomly selected isolates. It 117 
was also noted that there was a higher proportion of isolates carrying more than one gene of 118 
blaOXA-23, blaOXA-40 or ISAba1 upstream of blaOXA-51 in non-diabetic patients than in those 119 
with diabetes (10% and 1% respectively, chi squared test, χ2 = 9.085, d.f. = 1, p = 0.003). 120 
In the present study we find that carbapenem resistance is very prevalent in A. baumannii 121 
isolates from hospitals in Saudi Arabia, with isolates much more likely to be resistant than 122 
not. Worryingly, a very high percentage of isolates carry a VIM-type metallo-β-lactamase 123 
alongside high levels of carriage of the acquired carbapenemases blaOXA-23 and blaOXA-40. As 124 
has been noted previously for metallo-β-lactamases (Franklin et al., 2006; Peleg et al., 2005), 125 
the number of isolates carrying a gene for a VIM-type enzyme is much higher than the 126 
number of isolates phenotypically resistant to carbapenems, reinforcing the need for 127 
molecular diagnostics particularly in regions where there is a known problem with such 128 
organisms.  129 
Another health issue that is particularly acute in the Middle East in countries such as Saudi 130 
Arabia is the increasing number of patients diagnosed with diabetes mellitus (Danaei et al., 131 
2011). Previous studies have shown that diabetes is a significant risk factor in acquiring a 132 
serious infection with A. baumannii (Metan et al., 2009; Michalopoulos et al., 2011; Prata-133 
Rocha et al., 2012). To our knowledge, here we show for the first time that diabetic patients 134 
with an A. baumannii infection are more likely than non-diabetic patients to carry a 135 
carbapenem-resistant isolate. With the prevalence of diabetes increasing, this represents a real 136 
healthcare problem as it amplifies the risk posed to diabetics from infection with A. 137 
baumannii. Previously we demonstrated that particular A. baumannii clones were associated 138 
with diabetic patients from Saudi Arabia (Alsultan et al., 2009). In the present study there are 139 
also indications that the isolates harboured by diabetics and non-diabetics differ. The further 140 
characterisation of these isolates through typing and β-lactamase gene sequencing will allow 141 
us to establish whether there are particular bacterial clones that are associated with diabetic 142 
patients. 143 
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227 
Characteristic No. % No. %
Total isolates 196 100 75 100
No. diabetics 84 43 20 27
bla OXA-23 108 55 42 56
bla OXA-40 59 30 9 12
bla OXA-58 0 0 0 0
ISAba1 -bla OXA-51 7 4 0 0
ISAba1 178 91 57 76
ISAba2 9 5 1 1
ISAba3 19 10 0 0
IS18 0 0 0 0
bla VIM 182 93 72 96
Imipenem resistant 181 92 49 65
Meropenem resistant 186 95 49 65
Tigecycline resistant 25 13 9 12
Colistin resistant 2 1 0 0
Carbapenem resistant Random
 228 
 229 
Table 1: Presence of genotypic and phenotypic characteristics amongst isolates. 230 
231 
Carbapenem resistant
No. % No. % statistic d.f. p  value*
Total 84 43 112 57 - - -
bla OXA-23 46 55 62 57 0.086 1 0.9228
bla OXA-40 25 30 31 28 0.04 1 0.8410
ISAba1 78 93 97 89 0.839 1 0.5400
ISAba2 9 11 0 0 12.25 1 0.0028
ISAba3 16 19 3 3 14.193 1 0.0020
bla VIM 79 94 100 92 0.374 1 0.7213
Imipenem resistant 80 95 98 90 1.88 1 0.2914
Meropenem resistant 83 99 100 92 4.822 1 0.0672
Tigecycline resistant 5 6 20 18 6.465 1 0.0440
Random
Total 20 28 55 72 - - -
bla OXA-23 16 76 26 47 5.14 1 0.0460
bla OXA-40 0 0 9 16 3.719 1 0.0720
ISAba1 16 80 41 75 0.239 1 0.6250
Imipenem resistant 20 100 29 53 14.471 1 0.0006
Meropenem resistant 20 100 29 53 14.471 1 0.0006
Tigecycline resistant 0 0 9 16 3.898 1 0.0768
Diabetic Non-diabetic Chi Squared
232 
Table 2: Comparison of genotypic and phenotypic traits in diabetic and non-diabetic patients. 233 
*Corrected p values according to Benjamini and Hochberg False Discovery Rate (Benjamini 234 
& Hochberg, 1995), values in bold are significant at the 5% level. 235 
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